China Medical System signs exclusive deals for tetanus and rabies antibodies

SGX Filings2025-09-22

China Medical System Holdings Limited said on Sep, 22 2025 that its subsidiaries have entered into two exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for Vecantoxatug Injection and Silevimig Injection.

Under the agreements, the group gains exclusive commercialization rights for both products in mainland China and exclusive licensing rights across the Asia-Pacific region, the Middle East and North Africa. Each agreement will run for 10 years following Chinese marketing approval of the respective product and will automatically renew for additional 10-year periods.

Vecantoxatug is a recombinant humanized monoclonal antibody for passive immunization against tetanus. It obtained Breakthrough Therapy designation from China’s Center for Drug Evaluation in May 2024, its Phase III trial met the primary efficacy endpoint, and its new drug application was accepted on May, 22 2025.

Silevimig is a recombinant fully human bispecific antibody for passive immunization after suspected rabies exposure. A Phase III study showed non-inferior efficacy to human rabies immunoglobulin; its adult new drug application was accepted on Jan, 14 2025. A Phase III paediatric trial is underway following regulatory clearance in Jul, 2025.

China Medical System said the partnerships will broaden its portfolio in urgent prophylaxis for tetanus and rabies across key markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176749636?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176749636","market":"sg","top_or_hot":-1,"title":"China Medical System signs exclusive deals for tetanus and rabies antibodies","media":"SGX Filings","content":"<p>China Medical System Holdings Limited said on Sep, 22 2025 that its subsidiaries have entered into two exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for Vecantoxatug Injection and Silevimig Injection.</p>\n<p>Under the agreements, the group gains exclusive commercialization rights for both products in mainland China and exclusive licensing rights across the Asia-Pacific region, the Middle East and North Africa. Each agreement will run for 10 years following Chinese marketing approval of the respective product and will automatically renew for additional 10-year periods.</p>\n<p>Vecantoxatug is a recombinant humanized monoclonal antibody for passive immunization against tetanus. It obtained Breakthrough Therapy designation from China’s Center for Drug Evaluation in May 2024, its Phase III trial met the primary efficacy endpoint, and its new drug application was accepted on May, 22 2025.</p>\n<p>Silevimig is a recombinant fully human bispecific antibody for passive immunization after suspected rabies exposure. A Phase III study showed non-inferior efficacy to human rabies immunoglobulin; its adult new drug application was accepted on Jan, 14 2025. A Phase III paediatric trial is underway following regulatory clearance in Jul, 2025.</p>\n<p>China Medical System said the partnerships will broaden its portfolio in urgent prophylaxis for tetanus and rabies across key markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System signs exclusive deals for tetanus and rabies antibodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System signs exclusive deals for tetanus and rabies antibodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2025-09-22 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited said on Sep, 22 2025 that its subsidiaries have entered into two exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for Vecantoxatug Injection and Silevimig Injection.</p>\n<p>Under the agreements, the group gains exclusive commercialization rights for both products in mainland China and exclusive licensing rights across the Asia-Pacific region, the Middle East and North Africa. Each agreement will run for 10 years following Chinese marketing approval of the respective product and will automatically renew for additional 10-year periods.</p>\n<p>Vecantoxatug is a recombinant humanized monoclonal antibody for passive immunization against tetanus. It obtained Breakthrough Therapy designation from China’s Center for Drug Evaluation in May 2024, its Phase III trial met the primary efficacy endpoint, and its new drug application was accepted on May, 22 2025.</p>\n<p>Silevimig is a recombinant fully human bispecific antibody for passive immunization after suspected rabies exposure. A Phase III study showed non-inferior efficacy to human rabies immunoglobulin; its adult new drug application was accepted on Jan, 14 2025. A Phase III paediatric trial is underway following regulatory clearance in Jul, 2025.</p>\n<p>China Medical System said the partnerships will broaden its portfolio in urgent prophylaxis for tetanus and rabies across key markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1176749636","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176749636","pubTimestamp":1758546587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited said on Sep, 22 2025 that its subsidiaries have entered into two exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业签署破伤风和狂犬病抗体独家协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited said on Sep, 22 2025 that its subsidiaries have entered into two exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for Vecantoxatug Injection and Silevimig Injection.\nUnder the agreements, the group gains exclusive commercialization rights for both products in mainland China and exclusive licensing rights across the Asia-Pacific region, the Middle East and North Africa. Each agreement will run for 10 years following Chinese marketing approval of the respective product and will automatically renew for additional 10-year periods.\nVecantoxatug is a recombinant humanized monoclonal antibody for passive immunization against tetanus. It obtained Breakthrough Therapy designation from China’s Center for Drug Evaluation in May 2024, its Phase III trial met the primary efficacy endpoint, and its new drug application was accepted on May, 22 2025.\nSilevimig is a recombinant fully human bispecific antibody for passive immunization after suspected rabies exposure. A Phase III study showed non-inferior efficacy to human rabies immunoglobulin; its adult new drug application was accepted on Jan, 14 2025. A Phase III paediatric trial is underway following regulatory clearance in Jul, 2025.\nChina Medical System said the partnerships will broaden its portfolio in urgent prophylaxis for tetanus and rabies across key markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176749636","isCrawlerRequest":true}